JP2022502380A5 - - Google Patents
Info
- Publication number
- JP2022502380A5 JP2022502380A5 JP2021516643A JP2021516643A JP2022502380A5 JP 2022502380 A5 JP2022502380 A5 JP 2022502380A5 JP 2021516643 A JP2021516643 A JP 2021516643A JP 2021516643 A JP2021516643 A JP 2021516643A JP 2022502380 A5 JP2022502380 A5 JP 2022502380A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- antigen
- antibody
- binding fragment
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862735529P | 2018-09-24 | 2018-09-24 | |
| US62/735,529 | 2018-09-24 | ||
| US201962826131P | 2019-03-29 | 2019-03-29 | |
| US62/826,131 | 2019-03-29 | ||
| PCT/US2019/052558 WO2020068723A1 (en) | 2018-09-24 | 2019-09-24 | Method of providing safe administration of an anti-cd154 antibody |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022502380A JP2022502380A (ja) | 2022-01-11 |
| JP2022502380A5 true JP2022502380A5 (enExample) | 2022-10-03 |
Family
ID=69950835
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021516643A Withdrawn JP2022502380A (ja) | 2018-09-24 | 2019-09-24 | 抗ｃｄ１５４抗体の安全な投与を提供する方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20210317220A1 (enExample) |
| EP (1) | EP3856246A4 (enExample) |
| JP (1) | JP2022502380A (enExample) |
| CN (1) | CN112770774A (enExample) |
| AU (1) | AU2019347730A1 (enExample) |
| WO (1) | WO2020068723A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3185091A1 (en) * | 2020-07-08 | 2022-01-13 | Yuan Cheng | Stabilized formulations containing anti-ctla-4 antibodies |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101540823B1 (ko) * | 2007-03-30 | 2015-07-30 | 메디뮨 엘엘씨 | 항체 제제 |
| GB0718684D0 (en) * | 2007-09-24 | 2007-10-31 | Roche Products Ltd | Treatment method |
| US9028826B2 (en) * | 2011-04-04 | 2015-05-12 | The Trustees Of Dartmouth College | Methods of immune therapy with anti-CD154 antibodies having impaired FcR binding and/or complement binding properties |
| KR102434073B1 (ko) * | 2011-10-11 | 2022-08-18 | 비엘라 바이오, 인크. | Cd40l 특이적 tn3 유래 스카폴드 및 이의 사용 방법 |
| GB201501613D0 (en) * | 2015-01-30 | 2015-03-18 | Ucb Biopharma Sprl | Treatment of autoimmune disorders with CD154 antibodies |
| SG10201913431QA (en) * | 2015-07-14 | 2020-03-30 | Immunext Inc | Anti-cd154 antibody having improved binding, functional and safety characteristics and use in human immunotherapy |
| MY188405A (en) * | 2015-08-05 | 2021-12-08 | Janssen Biotech Inc | Anti-cd154 antibodies and methods of using them |
-
2019
- 2019-09-24 WO PCT/US2019/052558 patent/WO2020068723A1/en not_active Ceased
- 2019-09-24 CN CN201980062755.5A patent/CN112770774A/zh active Pending
- 2019-09-24 JP JP2021516643A patent/JP2022502380A/ja not_active Withdrawn
- 2019-09-24 US US17/274,512 patent/US20210317220A1/en not_active Abandoned
- 2019-09-24 AU AU2019347730A patent/AU2019347730A1/en not_active Abandoned
- 2019-09-24 EP EP19867314.7A patent/EP3856246A4/en not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023548858A5 (enExample) | ||
| US20240417455A1 (en) | Treatment for rheumatoid arthritis | |
| CA2146647C (en) | Treatment of autoimmune and inflammatory disorders | |
| AU2011210773B2 (en) | Methods of treating diabetes with Dll4 antagonists | |
| JP2013542194A5 (enExample) | ||
| EP3360896B1 (en) | Antibody to hepatitis b surface antigen and use thereof | |
| JP2024531151A5 (enExample) | ||
| EA034767B1 (ru) | Человеческие антитела к белку f респираторного синцитиального вируса и способы их применения | |
| RU2016133463A (ru) | Гуманизированные антитела с повышенной стабильностью | |
| KR20170020423A (ko) | 항-hsv 항체의 국소 적용 | |
| JP2024516698A5 (enExample) | ||
| JP2024540226A5 (enExample) | ||
| IL275884B1 (en) | Human antibodies to influenza hemagglutinin | |
| CN118434759A (zh) | 用抗-pd-l1/il-10融合蛋白治疗疾病的方法 | |
| JP2024517087A5 (enExample) | ||
| JP2022527542A5 (enExample) | ||
| JP2022534494A5 (enExample) | ||
| Guillevin | Clinical trials on systemic necrotizing vasculitides | |
| NZ777838B2 (en) | Anti-cd38 antibodies and pharmaceutical compositions thereof for the treatment of autoantibody-mediated autoimmune disease | |
| JP2023538369A5 (enExample) | ||
| Hermida et al. | Use of biologic agents in cutaneous emergencies | |
| NZ777838A (en) | Anti-cd38 antibodies and pharmaceutical compositions thereof for the treatment of autoantibody-mediated autoimmune disease | |
| Boogaerts | The use of intravenous immunoglobulins in bone marrow transplantation | |
| TW202302146A (zh) | 使用抗baffr抗體治療全身性紅斑狼瘡 | |
| Thomas et al. | Individual Drugs in Rheumatology |